Analysts See $-0.29 EPS for Immune Design Corp. (IMDZ)

April 27, 2018 - By Adrian Mccoy

Investors sentiment increased to 1.92 in 2017 Q4. Its up 0.65, from 1.27 in 2017Q3. It is positive, as 14 investors sold Immune Design Corp. shares while 12 reduced holdings. 24 funds opened positions while 26 raised stakes. 23.09 million shares or 94.39% more from 11.88 million shares in 2017Q3 were reported.
Moreover, Comml Bank Of Mellon has 0% invested in Immune Design Corp. (NASDAQ:IMDZ) for 122,073 shares. Dimensional Fund Advisors Lp reported 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Personal Capital Advsrs reported 24,000 shares. California-based Parallax Volatility Advisers L P has invested 0% in Immune Design Corp. (NASDAQ:IMDZ). Rhumbline Advisers holds 0% in Immune Design Corp. (NASDAQ:IMDZ) or 16,398 shares. Wells Fargo & Mn has invested 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Ny State Common Retirement Fund reported 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Deutsche Bank Ag reported 72,278 shares. Balyasny Asset Mgmt Ltd Com stated it has 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Fmr Ltd Liability Corp reported 0% stake. Pnc Ser Group Inc Inc invested in 0% or 113 shares. Legal And General Grp Inc Plc has invested 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Ecor1 Capital Ltd Liability Co invested 1.56% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). Thompson Davis & Inc has 250 shares. 17,882 were accumulated by Goldman Sachs Grp Inc Inc Inc.

Since October 27, 2017, it had 0 buys, and 5 selling transactions for $66,512 activity. Gombotz Wayne also sold $8,282 worth of Immune Design Corp. (NASDAQ:IMDZ) on Thursday, January 4. Shares for $10.99M were bought by COLUMN GROUP L P. ter Meulen Jan Henrik also sold $8,282 worth of Immune Design Corp. (NASDAQ:IMDZ) shares. $13,885 worth of Immune Design Corp. (NASDAQ:IMDZ) was sold by Brady Stephen R on Thursday, January 4. Shares for $33,247 were sold by Paya Carlos V on Thursday, January 4. Svennilson Peter bought 2.68 million shares worth $10.99M.

Analysts expect Immune Design Corp. (NASDAQ:IMDZ) to report $-0.29 EPS on May, 3.They anticipate $0.21 EPS change or 42.00 % from last quarter’s $-0.5 EPS. After having $-0.29 EPS previously, Immune Design Corp.’s analysts see 0.00 % EPS growth. The stock increased 4.29% or $0.15 during the last trading session, reaching $3.65. About 597,559 shares traded or 31.43% up from the average. Immune Design Corp. (NASDAQ:IMDZ) has declined 53.26% since April 27, 2017 and is downtrending. It has underperformed by 64.81% the S&P500.

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company has market cap of $175.66 million. It primarily develops oncology product candidates based on its ZVex and GLAAS product discovery platforms. It currently has negative earnings. The company's products include CMB305, which is in Phase 2 trial for the treatment of NY-ESO-1 tumor antigen; LV305 that is in Phase 1 trial for the treatment of patients with relapsed or metastatic melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1; and G100, an intratumoral immune activation product candidate for the treatment of patients with Merkel cell carcinoma and non-Hodgkin Lymphoma.

Immune Design Corp. (NASDAQ:IMDZ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.